SERIES9
health care portfolio series 9
|
|
DAILY DATA
as of
11/20/09
|
Portfolio Status
|
Secondary
|
|
Offer Price1
|
--
|
|
Bid Price2
|
$11.079600
|
|
Liquidation Price3
|
$10.916300
|
1 The "offer" price represents the net asset value of one unit
of a trust plus a transactional sales charge.
2 The "bid" price represents the net asset value of one unit
of a trust excluding deferred sales charge.
3 The "liquidation" price represents the net asset value of
one unit of a trust and includes any front-end and deferred sales charges accounted
for if investors liquidate units.
4 The Historical Annual Dividend Distribution is as of date of deposit. The amount of distributions of the Trust may be lower or greater than the above-stated
amount due to certain factors that may include, but are not limited to, a change
in the dividends paid by issuers, a change in Trust expenses or the sale or maturity
of securities in the portfolio. Fees and expenses of the Trust may vary as a result
of a variety of factors including the Trust's size, redemption activity, brokerage and
other transaction costs and extraordinary expenses.
|
DEPOSIT INFORMATION
|
Inception Date
|
1/28/2009
|
|
Mandatory Termination Date
|
1/26/2011
|
|
NASDAQ Ticker Symbol
|
CHCRIX
|
|
Inception Unit Price
|
$10.000000
|
|
Inception Bid Price
|
$9.900000
|
|
Inception Liquidation Price
|
$9.655000
|
|
Historical Annual Dividend Distribution4
|
--
|
|
Deferred Sales Charge Dates
5
|
Oct 2009
Nov 2009
Dec 2009
|
| CUSIP - Monthly-Cash |
18387A227 |
| CUSIP - Monthly-Reinvest |
18387A235 |
| CUSIP - Monthly-Fee/Cash |
18387A243 |
| CUSIP - Monthly-Fee/Reinvest |
18387A250 |
5 Early redemption of units will still cause payment of deferred sales charge.
|
|
|
|
Past performance is no guarantee of future results. Investment returns and principal value will fluctuate with changes in market conditions. Investors' units, when redeemed, may be worth more or less than their original cost.
|
|
|
|
INVESTMENT OBJECTIVE
The Health Care Portfolio ("Trust") seeks to maximize total return through capital appreciation with a secondary objective of current income.
|
PRINCIPAL INVESTMENT STRATEGY
The Trust consists of 39 stocks classified as being in the Health Care Sector by the Global Industry Classification Standard (“GICS”). The
Trust is diversified across the Health Care Sector, which includes the following industries: Biotechnology, Health Care Equipment and Supplies, Health Care Providers and Services, Life Sciences Tools and Services, and Pharmaceuticals. The Sponsor selects stocks for the portfolio that it believes have the potential to achieve the Trust’s investment objective.
|
|
|
|
SELECTION CRITERIA
The Sponsor selects U.S.-traded stocks that it believes are core holdings of a well-diversified health care portfolio. To select the portfolio, the Sponsor follows a very disciplined process that includes both quantitative and qualitative analysis. The Sponsor begins with the approximately 550 stocks of companies that are classified as being in the Health Care Sector, traded on U.S. exchanges, and are either components of the Russell 3000® Index (“R3K”) or have market capitalizations larger than the smallest company within the R3K. The Sponsor then reduces the size of this universe to approximately 250 stocks by performing quantitative screening, which may be primarily based on, but not limited to, the following factors:
- Valuation. The Sponsor may screen for reasonably valued stocks based on measures such as price-to-earnings, price-to-book, and price-to-cash flow.
- Growth. The Sponsor may screen for companies with a history of better than average growth of revenues and earnings.
- Profitability. The Sponsor may screen for companies with a history of consistent and high profitability as measured by return-on-assets, return-on-equity, gross margin and net margin.
The Sponsor then reduces the 250 securities to 39 stocks by performing qualitative analysis, which may be primarily based on, but not limited to, the following factors:
- Balance Sheet. The Sponsor favors companies which possess overall financial strength and exhibit balance sheet improvements relative to their peers and the marketplace.
- Industry Leadership. The Sponsor favors companies which possess a strong competitive position among their domestic and global peers.
- Valuation. The Sponsor favors stocks for which valuations appear to be attractive based on measures such as price-to-earnings, price-to-book, and price-to-cash flow.
- Growth. The Sponsor favors companies with a history of (and prospects for) better than average growth of revenues and earnings.
- Profitability. The Sponsor favors companies with a history of (and prospects for) consistent and high profitability as measured by return-on-assets, return-on-equity, gross margin and net margin.
The Russell 3000® Index
The Russell 3000® Index offers investors access to the broad U.S. equity universe representing approximately 98% of the U.S. market. The Russell 3000® is constructed to provide a comprehensive, unbiased, and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected.
|
|
|
|
RISKS AND OTHER CONSIDERATIONS
This Trust is not being offered for sale. This data is for informational purposes only.
As with all investments, you may lose some or all of your investment in the Trust. The Trust also might not perform as well as you expect. This can happen for reasons such as these:
- Stock prices can be volatile. The value of your investment may fall over time. Market value fluctuates in response to various factors. These can include stock market movements, purchases or sales of securities by the Trust, government policies, litigation, and changes in interest rates, inflation, the financial condition of the securities’ issuer or even perceptions of the issuer. Units of the Trust are not deposits of any bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
- The Sponsor does not actively manage the portfolio. The Trust will generally hold, and may continue to buy, the same securities even though a security’s outlook, market value or yield may have changed.
- Share prices or dividend rates on the stocks in the Trust may decline during the life of the Trust. There is no guarantee that the issuers of the securities will declare dividends in the future and, if declared, whether they will remain at current levels or increase over time.
- The Trust includes stocks issued by companies in the health care sector. General risks of companies in the health care sector include extensive competition, generic drug sales or the loss of patent protection, product liability litigation and increased government regulation.
- The Trust includes securities issued by small-capitalization and mid-capitalization companies. These stocks customarily involve more investment risk than large-capitalization or more seasoned stocks. Small-capitalization and mid-capitalization companies may have limited product lines, markets or financial resources and may be more vulnerable to adverse general market or economic developments.
- The Trust invests in American Depositary Receipts (“ADRs”). The Trust’s investment in ADRs presents additional risk. ADRs are issued by a bank or trust company to evidence ownership of underlying securities issued by foreign corporations. Securities of foreign issuers present risks beyond those of domestic securities. More specifically, foreign risk is the risk that foreign securities will be more volatile than U.S. securities due to such factors as adverse economic, currency, political, social or regulatory developments in a country, including government seizure of assets, excessive taxation, limitations on the use or transfer of assets, the lack of liquidity or regulatory controls with respect to certain industries or differing legal and/or accounting standards.
- The Trust may invest in companies that are considered to be passive foreign investment companies (“PFICs”). In general, PFICs are certain non-U.S. corporations that receive at least 75% of their annual gross income from passive sources (such as interest, dividends, certain rents and royalties or capital gains) or that hold at least 50% of their assets in investments producing such passive income. As a result of an investment in PFICs, the Trust could be subject to U.S. federal income tax and additional interest charges on gains and certain distributions with respect to those equity interests, even if all the income or gain is distributed to its unitholders in a timely manner. The Trust will not be able to pass through to its unitholders any credit or deduction for such taxes.
- Inflation may lead to a decrease in the value of assets or income from investments.
Please see the Trust prospectus for more complete risk information.
UITs are fixed and not actively managed. Investors can lose some or all of their investment in this Trust. An investment in this fixed portfolio should be made with an understanding of the risks involved with owning various types of investments. Industry predictions may not materialize and securities selected for the Trust may not participate in overall industry growth, if any. There is no guarantee that this portfolio will achieve its investment objective. The economic condition of the issuers of the securities in this portfolio as well as the stock market, in general, may worsen and therefore reduce the value of the units of the portfolio.
This UIT is part of a long-term strategy, and investors should consider their ability to invest in successive portfolios at the applicable sales charge, if available. There are tax consequences associated with an investment from one series to the next. Investors should consult their tax advisor to determine tax consequences associated with an investment from one portfolio to the next. Units of certain portfolios may be well suited for purchase by Individual Retirement Accounts or other qualified retirement plans. Consult your attorney or tax advisor regarding tax consequences associated with the purchase of units. Claymore Securities, Inc. does not offer tax advice.
|
|
|
|
|
Investors should carefully consider the investment objectives and policies, risk considerations, charges
and ongoing expenses of any investment product before investing. The prospectus contains this and other
relevant information. Please read the prospectus carefully before you invest. To obtain a prospectus,
please contact a securities representative or Claymore Securities, Inc., 2455 Corporate West Drive, Lisle,
Illinois 60532, 800-345-7999, or download one by accessing the Literature section
of this website.
NOT FDIC-INSURED | NOT BANK-GUARANTEED | MAY LOSE VALUE
|
|